SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Nephrology Consultation — Emily Dickinson — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.
| Patient | Emily Dickinson |
|---|
| Date of birth | 1830-12-10 |
|---|
| Identifiers | MRN HR-NI023-SYN-TD; SSN (made up) 000-23-6081 |
|---|
| Document date | 1885-02-02 |
|---|
| Author | Samuel Adeyemi, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Reason for Referral
Stage G3a A2 chronic kidney disease with hypertension in a 54-year-old woman without diabetes. Please confirm the probable cause, advise whether further tests are needed, and advise on kidney-protective treatment and follow-up. [S]
Urgency: Routine, within four weeks; please see her on the same morning as her kidney ultrasound, since she travels with difficulty. [S]
Questions for the consultant:
- Is hypertensive kidney disease the probable cause, or does she need further tests, such as serology or a kidney biopsy?
- Should she take an SGLT2 inhibitor, given that she does not have diabetes?
- What ARB dose and blood pressure target do you advise?
- How should the raised PTH and low vitamin D be managed at this stage?
- How often does she need nephrology follow-up, and can it be by video?
History of Present Illness
Ms. Dickinson is seen at the request of Dr. Hartwell for chronic kidney disease with albuminuria and newly treated hypertension. She has had morning headaches and nausea for several months and took naproxen for them until three weeks ago. A low eGFR and albuminuria were found fourteen months ago and not followed up, so the disease has lasted more than three months. She has no history of kidney disease in childhood, urinary infections, stones, rash, joint pain, or blood in the urine, and no diabetes. She takes no herbal remedies or proton pump inhibitors. She started losartan 50 mg three weeks ago. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
- Emily Dickinson was born on December 10, 1830, in the family Homestead on Main Street in Amherst, Massachusetts. [D]
- In the late winter of 1848 she was removed from Mount Holyoke Female Seminary for about a month because of lung congestion and a cough. [D]
- In 1851 she had symptoms then thought to be consumptive, consulted local and Boston doctors, and for two years took a glycerine prescription from a Boston tuberculosis specialist until the symptoms apparently subsided. [D]
- By her own account an eye affliction began in the fall of 1863; in February 1864 she consulted the Boston ophthalmologist Henry Willard Williams, lived in Cambridgeport from April to December 1864 to be near him for treatment, and repeated the treatment from April to October 1865, after which she was apparently cured. [D]
- The treatment required confinement in dim light, no reading, and writing only in pencil; she called her first stay in Cambridge eight months of Siberia. [D]
- No record of the eye diagnosis survives. Her main symptoms were sensitivity to light, aching eyes, and a restricted ability to do close work; iritis is considered the most likely explanation, and exotropia, a psychiatric cause, and hysterical hyperaesthesia of the retina have also been proposed. [R]
- Her withdrawal from normal social situations began in her mid-twenties; in later years she rarely went beyond the family Homestead and spoke with some visitors from behind a darkened door rather than face to face. [D]
- Scholars disagree whether her withdrawal was a deliberate artistic choice or had a medical origin, such as an anxiety condition. [R]
- A 2013 review by Hirschhorn and Longsworth rejects a proposed diagnosis of epilepsy on scientific, clinical, and biographical grounds. [R]
- Her death came after two and a half years of ill health that followed a death in her family in October 1883 and a consequent nervous prostration; she later had two blackouts and was confined to bed for the seven months before her death. [D]
- Her letters mention severe headache and nausea, and her last illness ended in a coma with raspy, difficult breathing. [D]
- Her reclusiveness hampered her Amherst physician, because she would not admit him to her bedside to take a pulse. [D]
- Researchers have concluded that she died of heart failure caused by severe hypertension; no documentary evidence records the yellow pallor and odor associated with nephritis. [R]
1 later historical claim is omitted because it describes events after the index age. See the teaching note.
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Naproxen sodium 220 mg oral tablet, two tablets by mouth as needed for headache (over the counter) | Two tablets as needed, up to twice a day | Oral route | 1884-10-01 to 1885-01-12 | stopped | S |
| Losartan 50 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1885-01-12 to 1885-02-02 | completed | S |
| Losartan 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1885-02-02 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1885-01-12 | active | S |
| Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1885-01-12 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a day | Two tablets every 6 hours as needed; maximum 6 tablets a day | Oral route | 1885-01-12 | active | S |
| Dapagliflozin 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1885-02-02 | active | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Chronic kidney disease stage G3a A2, attributed to hypertension; synthetic modern diagnosis linked to the Bright's disease entered on her death certificate | active | confirmed |
N18.31 | S — Synthetic modern diagnosis. Bright's disease as her recorded cause of death is documented (D); what it meant in her case is a retrospective question (R), and no kidney test from her lifetime exists. |
| Hypertension with chronic kidney disease (hypertensive chronic kidney disease, stage 3a); synthetic modern diagnosis linked to the retrospective view that she had severe hypertension | active | confirmed |
I12.9 | S — Synthetic modern diagnosis; severe hypertension is a retrospective interpretation (R, possible), and no blood pressure from her lifetime exists. |
| Vitamin D deficiency with a mildly raised PTH in chronic kidney disease | active | confirmed |
E55.9 | S — Synthetic laboratory finding at the intake visit. |
Physical Exam
Vital signs recorded on 1885-02-02; see the referring visit's Vital Signs section. [S]
| System | Finding |
|---|
| Vital signs | 148/88 mmHg seated after five minutes' rest, average of two readings; pulse 74 |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Abdomen | Soft; kidneys not palpable; no renal bruit |
| Skin and joints | No rash, purpura, or synovitis |
Results
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
| 1885-02-02 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 1885-02-02 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1885-02-02 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 24 | mmol/L | 22-29 mmol/L | Normal | S |
| 1885-02-02 | Urea nitrogen [Mass/volume] in Serum or Plasma | 22 | mg/dL | 6-21 mg/dL | High | S |
| 1885-02-02 | Creatinine [Mass/volume] in Serum or Plasma | 1.26 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 1885-02-02 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1880)/1.73 sq M | 51 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 1885-02-02 | Glucose [Mass/volume] in Serum or Plasma | 90 | mg/dL | 70-99 mg/dL | Normal | S |
| 1885-02-02 | Albumin/Creatinine [Mass Ratio] in Urine | 262 | mg/g | <=30 mg/g | High | S |
Assessment
- Chronic kidney disease G3a A2 (N18.31). Confirmed: eGFR 51 to 58 for more than three months, with albuminuria of 240 and 262 mg/g on two samples. Long-standing untreated hypertension, borderline left ventricular hypertrophy on ECG, a bland urine without red cells, and normal-sized, mildly echogenic kidneys on ultrasound make hypertensive kidney disease the probable cause, possibly worsened by regular naproxen. With no hematuria, systemic features, nephrotic-range albuminuria, or rapid decline, a biopsy or glomerular serology is not needed now. KFRE is low, at 1.6 percent over 5 years. [S]
- Hypertension with chronic kidney disease (I12.9). Above target on losartan 50 mg. Today's potassium of 4.6 mmol/L and creatinine of 1.26 mg/dL after three weeks allow the dose to be raised. [S]
- Vitamin D deficiency with a mildly raised PTH (E55.9). A PTH of 74 pg/mL at G3a with a low vitamin D is most likely from the vitamin D deficiency; calcium and phosphate are normal. [S]
Data reviewed: The intake results, the ECG, today's metabolic panel and second urine albumin-creatinine ratio, home blood pressure readings, and this morning's kidney ultrasound. [S]
Plan of Treatment
- Raise losartan to 100 mg daily, the maximum dose, for A2 albuminuria. [S]
- Start dapagliflozin 10 mg daily: KDIGO recommends an SGLT2 inhibitor in chronic kidney disease with eGFR of at least 20 and a urine albumin-creatinine ratio of at least 200 mg/g, with or without diabetes. [S]
- Recheck potassium and creatinine 2 to 4 weeks after these changes; accept a creatinine rise of up to 30 percent. [S]
- Aim for a standardized systolic pressure below 120 mmHg if tolerated; if home readings stay above target on the full ARB dose, add amlodipine. [S]
- Repeat the urine albumin-creatinine ratio about three months after starting treatment to judge the response, then eGFR and urine albumin twice a year. [S]
- Continue vitamin D3 1,000 units daily and recheck 25-hydroxyvitamin D, calcium, phosphate, and PTH in 6 to 12 months; no calcitriol. [S]
- No NSAIDs; written sick-day rules for losartan and dapagliflozin during vomiting, diarrhea, or poor intake. [S]
- Complete hepatitis B vaccination, as for all adults with chronic kidney disease. [S]
- Discussed with Dr. Hartwell the same morning. Ms. Dickinson agrees with the plan and asked for it in writing. [S]
- Follow-up: Primary care leads, with home and video visits. Nephrology video review in about a year with the yearly tests, or sooner if eGFR falls by more than 20 percent and stays down, the urine albumin-creatinine ratio doubles, potassium is above 5.5 mmol/L, or the 5-year KFRE reaches 3 percent. [S]